Inhibition by the combined Ca2+and 5-HT2receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage

Journal of Cardiovascular Pharmacology

Volumn 22, Issue 5, 1993, Pages 687-694

  Kirchengast, Michael ^a   Rübsamen, Klaus ^a   Lehmann, Hans D ^a  

^a Knoll AG   (Germany)

Author keywords

5 HT2Receptor blockade; Calcium antagonism; Cyclic coronary flow reductions; Nexopamil; Unstable angina

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; GALLOPAMIL; KETANSERIN; LU 49938; NEXOPAMIL; SEROTONIN 2 RECEPTOR; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; CALCIUM; DRUG DERIVATIVE; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY THROMBOSIS; DOG; HEART MUSCLE OXYGEN CONSUMPTION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; UNSTABLE ANGINA PECTORIS; ANIMAL; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; HEMODYNAMICS; MALE;

ANIMAL; CALCIUM; COMPARATIVE STUDY; CORONARY CIRCULATION; CORONARY THROMBOSIS; DOGS; FEMALE; GALLOPAMIL; HEMODYNAMICS; INJECTIONS, INTRAVENOUS; KETANSERIN; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; SEROTONIN ANTAGONISTS; VERAPAMIL;

EID: 0027330391     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/00005344-199311000-00003     Document Type: Article

References (42)

1. Maseri A, L'Abbate A, Pesola A, et al. Coronary vasospasm in angina pectoris. Lancet 1977;1:713-7.
2. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 1989;80:198-205.
3. Ambrose JA, Winters SL, Arora RR, et al. Coronary angiographic morphology in myocardial infarction: a link between the pathogenesis of unstable angina and myocardial infarction. J Am Coll Cardiol 1985;6:1233-8.
4. Hamm CW, Lorenz R, Bleifeld W, Kupper W, Wober W, Weber P. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol 1987;9:998-1004.
5. Van den Berg EK, Schmitz JM, Benedict CR, Malloy CR, Willerson JT, Dehmer GJ. Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology. Circulation 1989; 79:116-24.
6. Bush LR, Campbell WB, Tilton GD, Buja LM, Willerson JT. Effects of the selective thromboxane synthesis inhibitor, dazoxiben, on variations in cyclic blood flow in stenosed canine coronary arteries. Circulation 1984;69:1161-70.
7. 2receptor antagonists. Circ Res 1986;59:568-78.
8. Schmitz J, Apprill P, Buja LM, Willerson JT, Campbell WB. Vascular prostaglandin and thromboxane production in a canine model of myocardial ischaemia. Circ Res 1985;57:223-31.
9. Bush LR, Patrick D. The role of the endothelium in arterial thrombosis and the influence of antithrombotic therapy. Drug Dev Res 1986;7:319-40.
10. 2receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses. Circulation 1987;76:952-9.
11. Golino P, Buja LM, Ashton JH, Kulkami P, Taylor A, Willerson JT. Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet disposition in dogs with experimentally stenosed coronary arteries. Circulation 1988;78:701-11.
12. 2and serotonin are possible mediators. Circulation 1989;79:154-66.
13. Vanhoutte PM, Cohen RA, Van Nueten JM. Serotonin and arterial vessels. J Cardiovasc Pharmacol 1984;6(suppl 2):S421-8.
14. Ashton JH, Benedict CR, Fitzgerald C, et al. Serotonin is a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation 1986;73:572-8.
15. Rubanyi GM, Frye RL, Holmes DR, Vanhoutte PM. Vasoconstrictor activity of coronary sinus plasma from patients with coronary artery disease. J Am Coll Cardiol 1987;9:1243-9.
16. 2receptor antagonist ritenserin. Cardiovasc Res 1990;24:465-70.
17. 2receptor antagonist, of the formation of coronary thrombi in dogs. Cardiovasc Res 1991;25:727-30.
18. Belcher PR, Drake-Holland AJ, Hynd J, Noble MIM. Dispersion of coronary artery thrombi by antagonism of platelet serotonin receptor in the dog. Cardiovasc Res 1992;26:292-6.
19. Golino P, Piscione F, Willerson JT, et al. Divergent effect of serotonin on coronary artery dimensions and flood flow in patients with coronary arteriosclerosis and control patients. N Engl J Med 1991;324:641-8.
20. McFadden EP, Clarke JG, Davies GJ, Kaski JC, Haider AW, Maseri A. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med 1991;324:648-54.
21. McFadden EP, Bauters C, Lablanche JM, et al. Effect of ketanserin on proximal and distal coronary constrictor responses to intracoronary infusion of serotonin in patients with stable angina, patients with variant angina, and control patients. Circulation 1992;86:187-95.
22. Folts JD, Crowell EB, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976;54:365-70.
23. Folts JD. An in vivo model of experimental arterial stenosis, intimai damage, and periodic thrombosis. Circulation 1991;83(suppl IV):IV-3-14.
24. Nayler WG. Calcium antagonists. London: Academic Press, 1988.
25. Opie LH. Clinical use of calcium channel antagonist drugs. Boston: Kluwer Academic Publishers, 1990.
26. 2and serotonin as mediators of coronary artery vasoconstriction in vivo. J Am Coll Cardiol 1990;18:718-26.
27. Folts JD, Hamilton JW, Stone CK. Aspirin combined with amlodipine prevents acute platelet thrombus formation in stenosed dog coronary arteries. Fifth International Symposium on Calcium Antagonists. Pharmacol Clin Res 1991;58.
28. 2antagonistic properties. Naunyn Schmiedebergs Arch Pharmacol 1991;344(suppl):182.
29. 2+antagonist LU 49938 on bovine coronary arteries in vitro. Naunyn Schmiedebergs Arch Pharmacol 1991;343(suppl):254.
30. 2receptors in rat cerebral cortex by the calcium antagonists verapamil and D 600. Eur J Pharmacol 1984;41:431-5.
31. 2antagonist with potent action in hypertension and on coronary circulation. Naunyn Schmiedebergs Arch Pharmacol 1991;343(suppl):255.
32. 2receptors with promising potential in hypertension and coronary artery disease. Fifth International Symposium on Calcium Antagonists. Pharmacol Clin Res 1991;77.
33. Marquardt DW. An algorithm for least-squares estimation of non-linear parameters. J Soc Indus! Appl Math 1963;11:431-41.
34. Tabata T, Ho R. Effective treatment of the interpretation factor in Marquardt's non-linear least-squares fit algorithm. Compu J 1975;18:250-1.
35. De Feudis FV. Interactions of calcium antagonists with neurotransmitter receptors and neurotransmitter uptake processes-overview. Drugs Today 1987;23:347-61.
36. ++antagonists. TIPS 1988;9:352-3.
37. Hawiger JI, ed. Platelets: receptors, adhesion, secretion. San Diego: Academic Press, 1989.
38. Vanhoutte PM. Platelet-derived serotonin, the endothelium, and cardiovascular disease. J Cardiovasc Pharmacol 1991;17(suppl 5):S6-12.
39. Rubanyi GM. Endothelium, platelets and coronary vasospasm. Coronary Artery Dis 1990;1:645-53.
40. Nichols AJ, Ruffolo RR, Huffman WF, Poste G, Samonen J. Development of GPIIb/IIIa antagonists as antithrombotic drugs. TIPS 1992;13:413-7.
41. Willerson JT. Serotonin and thrombotic complications. J Cardiovasc Pharmacol 1991;17(suppl 5):S13-22.
42. Vanhoutte PM. Serotonergic antagonists and vascular disease. Cardiovasc Drugs Ther 1990;4:7-12.